20 November 2013Sequana Medical appoints Vingmed/ViCare Medical as distributor of the alfapump® system in Scandinavia
Sequana Medical is pleased to announce the appointment of Vingmed and ViCare as distributor for the alfapump system in Norway, Sweden and Denmark.
21 October 2013
NeoMed Innovation IV L.P. has been awarded the prize “Venture Capital Fund of the Year” for its outstanding results over the last 12 months. The award was received at the annual Norwegian Investment Forum, the largest venture capital conference in Norway attended by more than 200 delegates on 15. October 2013. This is the first time a fund exclusively investing in the healthcare industry is receiving this award.
15 October 2013Fiercemedicaldevices names JenaValve one of ‘Fierce 15’ Top Medical Device and Diagnostic Companies of 2013
JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the most promising private companies in the medical device industry in 2013. JenaValve was chosen as one of the Fierce 15 based, in part, on the innovation and promise of the JenaValve TAVI System.
18 September 2013Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis (AD).
18 September 2013Diagnoplex SA and Unilabs sign a collaboration agreement to market the Colox® noninvasive colon cancer screening test
Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer and Unilabs, a leading supplier of clinical laboratory and medical diagnostic imaging services in Europe, signed a collaboration agreement to commercialize Colox®, a minimally invasive colorectal cancer assay within the Unilabs network. The test will be available initially in the Swiss and Swedish markets.